|
|
PABPC4及MYC诱导形成的肝癌的研究进展
|
Abstract:
肝癌是影响人们健康的最常见癌症之一，具有高侵袭性、预后差及治疗选择有限的临床特点，已成为全球第六大常见癌症，致死率居全球第三。c-Myc是肝细胞肝癌(HCC)发育中的一个重要致癌基因，在18%的人类HCC中被发现被扩增或上调，但同时c-Myc是一种多效性转录因子，对正常细胞增殖和维持干细胞至关重要，尽管c-Myc抑制剂现在正在临床上进行测试，但仍有可能具有局限性。c-Myc致瘤作用及其下游调控的基因和信号通路仍有待充分研究，寻找新的早期诊断和靶向治疗分子等为肝癌的预防和治疗带来新的方法和策略。细胞质多聚腺苷酸结合蛋白4 (PABPC4)是一种RNA加工蛋白，在调节基因表达中起重要作用。越来越多的证据表明了PABPC4在肿瘤发生中的独特作用。本综述的目的是解释c-Myc在肿瘤发展中的作用以及PABPC4的研究现状。
Hepatocellular carcinoma is one of the most common cancers affecting people’s health. It has be-come the sixth most common cancer in the world and the third deadliest cancer in the world due to its high aggressiveness, poor prognosis and limited treatment options. c-Myc is an important onco-gene in HCC development and has been found to be amplified or upregulated in 18% of human HCC, but at the same time, c-Myc is a pleiotropic transcription factor that is essential for normal cell pro-liferation and maintenance of stem cells, and although c-Myc inhibitors are now being tested clini-cally, they are still likely to have limitations. The oncogenic effect of c-Myc and its downstream reg-ulation of genes and signaling pathways remain to be fully studied, and new early diagnosis and targeted therapeutic molecules are sought to bring new methods and strategies for the prevention and treatment of liver cancer. Cytoplasmic PABPC4 is an RNA processing protein that plays an im-portant role in regulating gene expression. There is increasing evidence for the unique role of PABPC4 in tumorigenesis. The purpose of this review is to explain the role of c-Myc in tumor devel-opment and the current status of PABPC4 research.
| [1] | Samant, H., Amiri, H.S. and Zibari, G.B. (2021) Addressing the Worldwide Hepatocellular Carcinoma: Epidemiology, Prevention and Management. Journal of Gastrointestinal Oncology, 12, S361-S373.
https://pubmed.ncbi.nlm.nih.gov/34422400/ https://doi.org/10.21037/jgo.2020.02.08 |
| [2] | Deng, S.S., Solinas, A. and Calvisi, D.F. (2021) Cabozantinib for HCC Treatment, from Clinical Back to Experimental Models. Frontiers in Oncology, 11, Article 756672. https://pubmed.ncbi.nlm.nih.gov/34722310/ https://doi.org/10.3389/fonc.2021.756672 |
| [3] | Ouyang, T., Kan, X.F. and Zheng, C.S. (2022) Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies. Frontiers in Oncology, 12, Article 898964.
https://pubmed.ncbi.nlm.nih.gov/35785169/ https://doi.org/10.3389/fonc.2022.898964 |
| [4] | Kim, D.W., Talati, C. and Kim, R. (2017) Hepatocellular Carcinoma (HCC): Beyond Sorafenib—Chemotherapy. Journal of Gastrointestinal Oncology, 8, 256-265. https://doi.org/10.21037/jgo.2016.09.07 |
| [5] | Ghaziani, T.T. and Dhanasekaran, R. (2021) Recent Progress in Sys-temic Therapy for Hepatocellular Cancer (HCC). Current Treatment Options in Gastroenterology, 19, 351-368. https://pubmed.ncbi.nlm.nih.gov/35530750/ https://doi.org/10.1007/s11938-021-00346-x |
| [6] | Zheng, K., Cubero, F. and Nevzorova, Y. (2017) c-MYC—Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease. Genes, 8, Article 123. https://doi.org/10.3390/genes8040123 |
| [7] | Poon, T.C.W., Wong, N., Lai, P.B.S., et al. (2006) A Tumor Progres-sion Model for Hepatocellular Carcinoma: Bioinformatic Analysis of Genomic Data. Gastroenterology, 131, 1262-1270. https://doi.org/10.1053/j.gastro.2006.08.014 |
| [8] | Su, W.H., Chao, C.C., Yeh, S.H., et al. (2007) OncoDB.HCC: An Integrated Oncogenomic Database of Hepatocellular Carcinoma Revealed Aberrant Cancer Target Genes and Loci. Nucleic Acids Research, 35, D727-D731.
https://doi.org/10.1093/nar/gkl845 |
| [9] | Kim, S., Li, Q., Dang, C.V. and Lee, L.A. (2000) Induction of Ribosomal Genes and Hepatocyte Hypertrophy by Adenovirus-Mediated Expression of c-Myc in Vivo. Proceedings of the National Academy of Sciences of the United States of America, 97, 11198-11202. https://www.pnas.org/doi/full/10.1073/pnas.200372597 https://doi.org/10.1073/pnas.200372597 |
| [10] | Kawate, S., Fukusato, T., Ohwada, S., et al. (1999) Amplification of c-myc in Hepatocellular Carcinoma: Correlation with Clinicopathologic Features, Proliferative Activity and p53 Overex-pression. Oncology, 57, 157-163.
https://doi.org/10.1159/000012024 |
| [11] | Dang, C.V. (2012) MYC on the Path to Cancer. Cell, 149, 22-35. https://doi.org/10.1016/j.cell.2012.03.003 |
| [12] | Sanders, J.A. and Gruppuso, P.A. (2005) Nucleolar Localization of Hepatic c-Myc: A Potential Mechanism for c-Myc Regulation. Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, 1743, 141-150.
https://doi.org/10.1016/j.bbamcr.2004.09.009 |
| [13] | Ceni, E., Mello, T. and Galli, A. (2014) Pathogenesis of Alco-holic Liver Disease: Role of Oxidative Metabolism. World Journal of Gastroenterology, 20, 17756-17772. https://doi.org/10.3748/wjg.v20.i47.17756 |
| [14] | Yilma, M., Saxena, V. and Mehta, N. (2022) Models to Predict Development or Recurence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis. Current Gastroenterology Reports, 24, 1-9.
https://pubmed.ncbi.nlm.nih.gov/35142988/ https://doi.org/10.1007/s11894-022-00835-8 |
| [15] | Nevzorova, Y.A., Cubero, F.J., Hu, W., et al. (2016) Enhanced Expression of c-myc in Hepatocytes Promotes Initiation and Progression of Alcoholic Liver Disease. Journal of Hepa-tology, 64, 628-640.
https://doi.org/10.1016/j.jhep.2015.11.005 |
| [16] | Kaposi-Novak, P., Libbrecht, L., Woo, H.G., et al. (2009) Central Role of c-Myc during Malignant Conversion in Human Hepatocarcinogenesis. Cancer Research, 69, 2775-2782. https://doi.org/10.1158/0008-5472.CAN-08-3357 |
| [17] | Jonghwan Kim, et al. (2010) A Myc Network Accounts for Similarities between Embryonic Stem and Cancer Cell Transcription Programs. Cell, 143, 313-324. https://pubmed.ncbi.nlm.nih.gov/20946988/ https://doi.org/10.1016/j.cell.2010.09.010 |
| [18] | Attallah, A.M., El-Far, M., Omran, M.M., et al. (2016) GPC-HCC Model: A Combination of Glybican-3 with Other Routine Parameters Improves the Diagnostic Efficacy in Hepatocellular Carcinoma. Tumour Biology, 37, 12571-12577. https://doi.org/10.1007/s13277-016-5127-6 |
| [19] | Shachaf, C.M., Kopelman, A.M., Arvanitis, C., et al. (2004) MYC Inactivation Uncovers Pluripotent Differentiation and Tumour Dor-mancy in Hepatocellular Cancer. Nature, 431, 1112-1117. https://doi.org/10.1038/nature03043 |
| [20] | Beroukhim, R., Mermel, C.H., Porter, D., et al. (2010) The Landscape of Somatic Copy-Number Alteration across Human Cancers. Na-ture, 463, 899-905. https://doi.org/10.1038/nature08822 |
| [21] | Niitsu, N., Okamoto, M., Miura, I. and Hirano, M. (2009) Clinical Features and Prognosis of De Novo Diffuse Large B-Cell Lymphoma with t(14;18) and 8q24/c-MYC Translocations. Leukemia, 23, 777-783.
https://doi.org/10.1038/leu.2008.344 |
| [22] | Emre Seli, et al. (2005) An Embryonic Poly(A)-Binding Protein (ePAB) Is Expressed in Mouse Oocytes and Early Preimplantation Embryos. Proceedings of the National Academy of Sciences of the United States of America, 102, 367-372. https://pubmed.ncbi.nlm.nih.gov/15630085/ https://doi.org/10.1073/pnas.0408378102 |
| [23] | Goss, D.J. and Kleiman, F.E. (2013) Poly(A) Binding Proteins: Are They All Created Equal? Wiley Interdisciplinary Reviews RNA, 4, 167-179. https://doi.org/10.1002/wrna.1151 |
| [24] | Kühn, U. and Wahle, E. (2004) Structure and Function of Poly(A) Binding Proteins. Biochimica Et Biophysica Acta, 1678, 67-84. |
| [25] | Passmore, L.A. and Coller, J. (2022) Roles of mRNA Poly(A) Tails in Regulation of Eukaryotic Gene Expression. Nature Reviews Molecular Cell Biology, 23, 93-106. https://doi.org/10.1038/s41580-021-00417-y |
| [26] | Khanam, T., Muddashetty, R.S., Kahvejian, A., Sonenberg, N. and Brosius, J. (2006) Poly(A)-Binding Protein Binds to A-Rich Sequences via RNA-Binding Domains 1+2 and 3+4. RNA Biology, 3, 170-177.
https://pubmed.ncbi.nlm.nih.gov/17387282/ https://doi.org/10.4161/rna.3.4.4075 |
| [27] | Zhu, Y.F. and Qi, M. (2020) Expression and Prognostic Roles of PABPC1 in Hepatocellular Carcinoma. International Journal of Surgery, 84, 3-12. https://doi.org/10.1016/j.ijsu.2020.10.004 |
| [28] | Ozturk, S. (2019) The Translational Functions of Embryonic Poly(A)-Binding Protein during Gametogenesis and Early Embryo Development. Molecular Reproduction and Devel-opment, 86, 1548-1560. https://doi.org/10.1002/mrd.23253 |
| [29] | Bernstein, P., Peltz, S.W. and Ross, J. (1989) The Poly(A)-Poly(A)-Binding Protein Complex Is a Major Determinant of mRNA Stability in Vitro. Molecular and Cellular Biology, 9, 659-670. https://pubmed.ncbi.nlm.nih.gov/2565532/ https://doi.org/10.1128/mcb.9.2.659-670.1989 |
| [30] | Gorgoni, B. and Gray, N.K. (2004) The Roles of Cytoplasmic Poly(A)-Binding Proteins in Regulating Gene Expression: A Developmental Perspective. Briefings in Functional Ge-nomics & Proteomics, 3, 125-141.
https://doi.org/10.1093/bfgp/3.2.125 |
| [31] | Sladic, R.T., Lagnado, C.A., Bagley, C.J. and Goodall, G.J. (2004) Hu-man PABP Binds AU-Rich RNA via RNA- Binding Domains 3 and 4. European Journal of Biochemistry, 271, 450-457.
https://pubmed.ncbi.nlm.nih.gov/14717712/ https://doi.org/10.1046/j.1432-1033.2003.03945.x |
| [32] | Yang, H., Duckett, C.S. and Lindsten, T. (1995) iPABP, an Inducible Poly(A)-Binding Protein Detected in Activated Human T Cells. Molecular and Cellular Biology, 15, 6770-6776. https://pubmed.ncbi.nlm.nih.gov/8524242/ https://doi.org/10.1128/MCB.15.12.6770 |
| [33] | Oliveira, A.G., Oliveira, L.D., Cruz, M.V., et al. (2023) Interaction between Poly(A)-Binding Protein PABPC4 and Nuclear Receptor Corepressor NCoR1 Modulates a Metabolic Stress Response. The Journal of Biological Chemistry, 299, Article ID: 104702. https://doi.org/10.1016/j.jbc.2023.104702 |
| [34] | Burgess, H.M., Richardson, W.A., Anderson, R.C., et al. (2011) Nuclear Relocalisation of Cytoplasmic Poly(A)- Binding Proteins PABP1 and PABP4 in Response to UV Irradiation Reveals mRNA-Dependent Export of Metazoan PABPs. Journal of Cell Science, 124, 3344-3355. https://doi.org/10.1242/jcs.087692 |
| [35] | Xie, J., Wei, X. and Chen, Y. (2021) Loss of PABPC1 Is Compensated by Elevated PABPC4 and Correlates with Transcriptome Changes. Biochemistry. https://doi.org/10.1101/2021.02.07.430165 |
| [36] | Jiang, X., Wang, G., Liu, Y., et al. (2021) A Novel Long Non-Coding RNA RP11-286H15.1 Represses Hepatocellular Carcinoma Progression by Promoting Ubiquitination of PABPC4. Cancer Letters, 499, 109-121.
https://doi.org/10.1016/j.canlet.2020.11.038 |
| [37] | Liu, D., Yin, B., Wang, Q., et al. (2012) Cytoplasmic Poly(A) Binding Protein 4 Is Highly Expressed in Human Colorectal Cancer and Correlates with Better Prognosis. Journal of Genetics and Genomics, 39, 369-374.
https://doi.org/10.1016/j.jgg.2012.05.007 |
| [38] | Guo, W., Li, J., Huang, H., et al. (2021) LncRNA PCIR Is an On-cogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer. Frontiers in Oncol-ogy, 11, Article 630300.
https://doi.org/10.3389/fonc.2021.630300 |
| [39] | Gu, Y., Wei, X., Sun, Y., et al. (2019) miR-192-5p Silencing by Genetic Aberrations Is a Key Event in Hepatocellular Carcinomas with Cancer Stem Cell Features. Cancer Research, 79, 941-953.
https://doi.org/10.1158/0008-5472.CAN-18-1675 |
| [40] | Kini, H.K., Kong, J. and Liebhaber, S.A. (2014) Cytoplas-mic Poly(A) Binding Protein C4 Serves a Critical Role in Erythroid Differentiation. Molecular and Cellular Biology, 34, 1300-1309. https://pubmed.ncbi.nlm.nih.gov/24469397/ https://doi.org/10.1128/MCB.01683-13 |
